Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. Pairawan S, et al. Among authors: dumbrava ei. Breast Cancer Res. 2021 Mar 4;23(1):29. doi: 10.1186/s13058-021-01406-x. Breast Cancer Res. 2021. PMID: 33663585 Free PMC article.
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.
Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. Owusu-Brackett N, et al. Among authors: dumbrava ei. Oncotarget. 2019 Aug 20;10(49):5011-5019. doi: 10.18632/oncotarget.27082. eCollection 2019 Aug 20. Oncotarget. 2019. PMID: 31489111 Free PMC article.
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.
Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Dumbrava EI, et al. JCO Precis Oncol. 2019;3:PO.18.00143. doi: 10.1200/PO.18.00143. Epub 2019 Apr 11. JCO Precis Oncol. 2019. PMID: 31517177 Free PMC article.
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Subbiah V, et al. Among authors: dumbrava ei. Exp Hematol Oncol. 2020 Apr 20;9:7. doi: 10.1186/s40164-020-00159-1. eCollection 2020. Exp Hematol Oncol. 2020. PMID: 32337094 Free PMC article.
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.
Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Pairawan S, et al. Among authors: dumbrava ei. Sci Rep. 2022 Jan 24;12(1):1248. doi: 10.1038/s41598-022-05193-z. Sci Rep. 2022. PMID: 35075200 Free PMC article.
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Nelson BE, et al. Cancer. 2023 Jul 15;129(14):2201-2213. doi: 10.1002/cncr.34773. Epub 2023 Apr 4. Cancer. 2023. PMID: 37016732 Free article. Clinical Trial.
Engineered T-cell Receptor T Cells for Cancer Immunotherapy.
Greenbaum U, Dumbrava EI, Biter AB, Haymaker CL, Hong DS. Greenbaum U, et al. Among authors: dumbrava ei. Cancer Immunol Res. 2021 Nov;9(11):1252-1261. doi: 10.1158/2326-6066.CIR-21-0269. Cancer Immunol Res. 2021. PMID: 34728535 Review.
14 results